– Staccato® Alprazolam could be a potential solution for 20-30% of epilepsy patients – Initial upfront payment of US$ 125 million and further potential milestone payments of up to US$ 145 million, total potential consideration of up to US$ 270 …
Trending at Lumira Ventures
Engage Therapeutics’ Phase 2b StATES Study Meets Primary Endpoint
SUMMIT, N.J. (GLOBE NEWSWIRE) — Engage Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on developing an orally inhaled therapy designed to terminate an active epileptic seizure, today announced that its Phase 2b StATES study of Staccato® alprazolam met its primary …
Epilepsia Publishes Phase 2a Data for Staccato Alprazolam
– Staccato alprazolam is shown to rapidly suppress seizure activity at two minutes in five patients with epilepsy – – Staccato alprazolam generally well tolerated; no serious or severe adverse events reported – – Enrollment in Phase 2b, double-blind, placebo-controlled …
Engage Therapeutics Presents Data from Part 1, Open-label Run-in of StATES Phase 2b Study of Staccato® Alprazolam at 2019 American Academy of Neurology Annual Meeting
8 patients with predictable generalized or focal epileptic seizures treated with Staccato alprazolam 62.5% of patients respond with the cessation of seizure activity within two minutes of therapy administration and no recurrence of seizure activity within two hours Feasibility of …
Engage Therapeutics Inc. to Present Phase 2b Data from StATES Study at 2019 American Academy of Neurology Annual General Meeting
SUMMIT, N.J. (PRNewswire) — Engage Therapeutics, Inc., a clinical-stage biopharmaceutical company developing a Rapid Epileptic Seizure Termination (REST) therapy for people who experience a predictable pattern of epileptic seizures, today announced it will present clinical data from the open-label portion of the …
Engage Therapeutics Successfully Completes Open Label Portion of Phase 2b StATES Study and Begins Enrollment in Double-Blind Placebo-Controlled Portion
Trial evaluating safety and efficacy of Staccato Alprazolam in subjects with epilepsy and a predictable seizure pattern Results from the open label portion of the study will be presented at a major medical meeting in 2019 NEW ORLEANS, Dec. 03, …
Engage Therapeutics Doses First Patient in Phase 2b Trial of Epilepsy Seizure Rescue Therapy Staccato® Alprazolam
Topline Data Expected H2-2019 Peachtree BioResearch Solutions to Execute Multi-Center Trial SUMMIT, N.J., May 03, 2018 (GLOBE NEWSWIRE) — Engage Therapeutics, Inc., today announced dosing of the first patient in its multi-center, double-blind, randomized Phase 2b StATES (Seizures) trial to …